A phase II study of lenalidomide in patients with relapsed or refractory ATLL

被引：0
|
作者：
Adrienne A Phillips
Jalanni Giddings
Steven M Horwitz
机构：
[1] Herbert Irving Cancer Center,Division of Medical Oncology, Department of Medicine
[2] Herbert Irving Cancer Center,Department of Medicine
[3] Memorial Sloan Kettering Cancer Center,undefined
来源：
Retrovirology | / 11卷 / Suppl 1期
关键词：
Median Survival; Thrombocytopenia; Median Number; Evaluable Patient; Single Institution;
D O I：
10.1186/1742-4690-11-S1-P4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Vesole, David H.
    Bilotti, Elizabeth
    Richter, Joshua R.
    McNeill, Ann
    McBride, Laura
    Raucci, Laura
    Anand, Palka
    Bednarz, Urszula
    Ivanovski, Kristin
    Smith, Judith
    Batra, Veena
    Aleman, Adolfo
    Sims, Taliah
    Guerrero, Laura
    Mato, Anthony
    Siegel, David S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 52 - 59
  • [32] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
  • [33] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [34] A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
    Cavallo, Federica
    Larocca, Alessandra
    Petrucci, Maria Teresa
    Federico, Vincenzo
    Falcone, Antonietta Pia
    Sanpaolo, Grazia
    Canepa, Letizia
    Crugnola, Monica
    Boccadoro, Mario
    Palumbo, Antonio
    BLOOD, 2009, 114 (22) : 1118 - 1118
  • [35] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
    Zekri, JM
    Hough, RE
    Davies, JM
    Molife, R
    Hancock, BW
    Lorigan, PC
    BRITISH JOURNAL OF CANCER, 2003, 88 (09) : 1335 - 1338
  • [37] Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
    J M Zekri
    R E Hough
    J M Davies
    R Molife
    B W Hancock
    P C Lorigan
    British Journal of Cancer, 2003, 88 : 1335 - 1338
  • [38] Lenalidomide In Patients with Relapsed or Refractory Hodgkin Lymphoma
    Boll, Boris
    Fuchs, Michael
    Reiners, Katrin S.
    Engert, Andreas
    Borchmann, Peter
    BLOOD, 2010, 116 (21) : 1166 - 1167
  • [39] Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Alsina, M.
    Ghobrial, I.
    Knight, R.
    Esseltine, D.
    Richardson, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
    Fehniger, Todd A.
    Larson, Sarah
    Trinkaus, Kathryn
    Siegel, Marilyn J.
    Cashen, Amanda F.
    Blum, Kristie A.
    Fenske, Timothy S.
    Hurd, David D.
    Goy, Andre
    Schneider, Stephanie E.
    Keppel, Catherine R.
    Wagner-Johnston, Nina D.
    Carson, Kenneth R.
    Bartlett, Nancy L.
    BLOOD, 2011, 118 (19) : 5119 - 5125
12345